Materiały źródłowe

• #1 Hepatitis C – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hepatitis-c/symptoms-causes/syc-20354278

  Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it. […] Newer antiviral medicines are the treatment of choice for most people with the ongoing, called chronic, hepatitis C infection. These medicines often can cure chronic hepatitis C. […] Chronic hepatitis C follows the same course no matter what the genotype of the infecting virus. But treatment can vary depending on viral genotype. However, newer antiviral drugs can treat many genotypes. […] Hepatitis C infection that continues over many years can cause serious complications, such as: Scarring of the liver, called cirrhosis. Scarring can occur after decades of hepatitis C infection. Liver scarring makes it hard for the liver to work. […] Liver cancer. A small number of people with hepatitis C infection get liver cancer. […] Liver failure. A lot of scarring can cause the liver to stop working.

• #2 What are the New Treatments for Hepatitis C? | Austin Gastroenterology

  https://www.austingastro.com/2024/01/26/what-are-the-new-treatments-for-hepatitis-c/

  Hepatitis C is a viral infection that threatens the health of your liver. Serious complications can arise from untreated hepatitis C, such as liver failure and liver cancer. However, early treatment can help prevent these complications. […] There was a time when there was no cure for hepatitis C, however advancements in treatment have made the condition a curable disease. The latest breakthroughs in the treatment of hepatitis C involve the use of highly effective antiviral medications. […] The main objective is to clear the hepatitis C virus from the bloodstream, achieving sustained virologic response (SVR). This means that after completing treatment, the virus is no longer detectable in the body. SVR is a measure of successful treatment and indicates a cure for hepatitis C. […] Successful treatment of hepatitis C can significantly reduce the chances of developing cirrhosis (severe liver scarring) and liver cancer. By eliminating the virus and managing liver inflammation, the risk of long-term complications associated with hepatitis C is minimized.

• #3 Hepatitis C Treatment Options

  https://www.webmd.com/hepatitis/understanding-hepatitis-c-treatment

  Hepatitis C is the No. 1 cause of liver cancer and liver transplants. It’s curable. But curing it hasn’t always been easy or comfortable. For decades, you needed painful shots of a medicine called interferon and a pill called ribavirin. These drugs didn’t target the virus that made you sick. Instead, they amped up your immune system so you’d fight it the way you do when you get the flu. […] These days, more and more people can get rid of the virus by simply taking a pill, at home, for just a few weeks. There are several ways to do it without having to get shots. […] Most of the time, these meds remove all traces of the virus from your blood within 12 weeks. This is called sustained virologic response (SVR), and its what doctors look for to tell if you’re cured. How long you’ll need treatment can vary. It may range from 8 to 24 weeks.

• #4 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. […] Therefore, the panel continues to recommend treatment for all patients with chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy. […] A well-established therapeutic relationship between clinician and patient remains crucial for optimal outcomes with direct-acting antiviral (DAA) therapies. […] The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response.

• #5 Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin

  https://emedicine.medscape.com/article/177792-treatment

  The treatment goal of HCV-infected individuals is the reduction of all-cause mortality and hepatic-associated morbidity (eg, end-stage liver disease, hepatocellular carcinoma) as achieved by virologic cure, with sustained virologic response. […] Hepatitis C has become a curable disease with the use of antiviral agents (95%). […] Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD), in collaboration with the International Antiviral Society-USA (IAS-USA). […] The AASLD/IDSA guidelines previously proposed that because all patients cannot receive treatment immediately upon the approval of new agents, priority should be given to those with the most urgent need. […] The AASLD/IDSA guidelines removed their prioritization tables but continue to strongly recommend treatment for all patients with acute or chronic HCV infection, barring those with shortened life expectancies that cannot be resolved by HCV treatment, liver transplantation, or another directed therapy.

• #6 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Treatment is recommended for all patients with acute or chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. […] The proximate goal of HCV therapy is SVR (virologic cure), defined as the continued absence of detectable HCV RNA for at least 12 weeks after completion of therapy. […] Patients who are cured of their HCV infection experience numerous health benefits, including a decrease in liver inflammation as reflected by improved aminotransferase levels (ie, alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), and a reduction in the rate of liver fibrosis progression. […] Among HCV-infected persons, SVR is associated with a 70% reduction in the risk of liver cancer (hepatocellular carcinoma [HCC]), and a 90% reduction in the risk of liver-related mortality and liver transplantation.

• #7 Clinical Care of Hepatitis C | Hepatitis C | CDC

  https://www.cdc.gov/hepatitis-c/hcp/clinical-care/index.html

  Hepatitis C can be cured in more than 95% of cases with just 8-12 weeks of well-tolerated oral-only treatment with direct-acting antiviral (DAA) agents. […] Curative DAA treatment is recommended for essentially everyone with hepatitis C. […] Available therapies can cure more than 95% of people infected with HCV within 812 weeks of therapy. […] Except for pregnant patients and children under 3, clinicians should treat people with detectable HCV RNA in their blood with oral DAA therapy. There is no need to wait for potential spontaneous viral resolution. […] DAA therapies are not approved for pregnant patients and children under 3. […] Your patient is considered cured of hepatitis C if there is no detectable HCV RNA after 12 weeks of treatment. This indicates they have had a sustained virologic response to therapy.

• #8

  https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

  Direct-acting antiviral medicines (DAAs) can cure more than 95% of persons with hepatitis C infection, but access to diagnosis and treatment is low. […] There are effective treatments for hepatitis C. The goal of treatment is to cure the disease and prevent long-term liver damage. […] Antiviral medications, including sofosbuvir and daclatasvir, are used to treat hepatitis C. Some people’s immune system can fight the infection on their own and new infections do not always need treatment. Treatment is always needed for chronic hepatitis C. […] WHO recommends therapy with pan-genotypic direct-acting antivirals (DAAs) for all adults, adolescents and children down to 3 years of age with chronic hepatitis C infection. The short-course oral, curative DAA treatment regimens has few if any side-effects. DAAs can cure most persons with HCV infection, and treatment duration is short (usually 12 to 24 weeks), depending on the absence or presence of cirrhosis.

• #9 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C virus is treated with all-oral medications. These pills, called antiviral medications, are usually taken once per day. These antiviral medications are extremely good at attacking the virus and preventing it from multiplying. […] Antiviral medications were not the original treatment for hepatitis C. Before 2014, the only treatment for hepatitis C was called interferon and ribavirin, taken as weekly injections under the skin, plus pills. Interferon treatment caused many unpleasant side effects and was not usually successful. Then a new generation of medications became available. These antiviral treatments are extremely successful at curing the virus and have very minimal side effects. […] The purpose of taking antiviral medications for hepatitis C is to: remove (or clear) all the hepatitis C virus from your body permanently, stop or slow down the damage to your liver, reduce the risk of developing cirrhosis (advanced scarring of the liver), reduce the risk of developing liver cancer (hepatocellular carcinoma), reduce the risk of liver failure and the need for a liver transplant.

• #10 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C virus is treated with all-oral medications. These pills, called antiviral medications, are usually taken once per day. These antiviral medications are extremely good at attacking the virus and preventing it from multiplying. […] Antiviral medications were not the original treatment for hepatitis C. Before 2014, the only treatment for hepatitis C was called interferon and ribavirin, taken as weekly injections under the skin, plus pills. Interferon treatment caused many unpleasant side effects and was not usually successful. Then a new generation of medications became available. These antiviral treatments are extremely successful at curing the virus and have very minimal side effects. […] The purpose of taking antiviral medications for hepatitis C is to: remove (or clear) all the hepatitis C virus from your body permanently, stop or slow down the damage to your liver, reduce the risk of developing cirrhosis (advanced scarring of the liver), reduce the risk of developing liver cancer (hepatocellular carcinoma), reduce the risk of liver failure and the need for a liver transplant.

• #11 Clinical Guidelines for the Medical Management of Hepatitis C

  https://www.health.ny.gov/publications/1852/treatment.htm

  The primary goal of HCV therapy is to achieve a SVR, defined as an undetectable HCV RNA 6 months after stopping antiviral therapy. Secondary goals of antiviral therapy include improvements in histology, quality of life and prevention of hepatocellular carcinoma. Antiviral therapy is approved by the Food and Drug Administration (FDA) for patients with persistently abnormal liver enzymes, detectable HCV RNA and an abnormal liver biopsy. Recent data have shown that patients with normal liver enzymes, detectable HCV RNA and an abnormal liver biopsy respond to therapy at similar rates as those with abnormal liver enzymes. […] […] The efficacy of HCV treatment has improved over the past decade. Initial treatment consisting of interferon alpha has been replaced by pegylated interferon and now by combination therapy using pegylated interferon and ribavirin. Efficacy varies depending on multiple factors especially viral genotype, but achieving sustained viral suppression in 50% of patients can be expected. […]

• #12 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Hepatitis-C-treatment-no-benefits-and-possible-harm.aspx

  Originally, hepatitis C was treated just with interferon (IFN) injections, usually three times per week. […] Combination treatment with some or all of these medications is now able to achieve SVR rates in excess of 60%. […] The treatment has not been proven to be efficacious with regard to preventing clinically important disease, it is expensive, and it causes substantial morbidity (including death). […] It is an inappropriate clinical decision to prescribe a toxic therapy (especially an expensive one) that has never been shown to provide clinical benefit in properly-done randomized trials. […] Peg-IFN also caused a number of adverse events, including infections, flu-like symptoms, fatigue, muscle aches, fever, rash, and lowering of white blood cell and platelet counts. […] These antiviral drugs are not free of medical or financial costs.

• #13

  https://www.hepcmyway.com/blog/a-history-of-hep-c-treatment

  The first approved antiviral Hep C medications for chronic HCV infection — interferon alfa-2b and ribavirin — were approved by the FDA in 1998. […] In the last few years, there have been major advancements in the development of more effective and tolerable antiviral medications for the treatment of HCV. […] These are the types of medications we typically prescribe at HepCMyWay. DAAs are taken orally, they have very few side effects, and they’re much more effective than interferon and ribavirin. In fact, treatment with DAAs can cure Hepatitis C in more than 95 percent of cases. […] As you can see, there have been major advancements in the diagnosis and treatment of Hepatitis C over the last few decades. And researchers are still working hard to develop even more effective and tolerable HCV treatments.

• #14 Current and future strategies for the treatment of chronic hepatitis C

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8046635/

  Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct acting antiviral agents has revolutionized the treatment of hepatitis C with finite, highly effective, well-tolerated therapy and there are few populations that cannot be successfully treated now or are complicated to manage. […] The introduction of all oral direct acting antiviral agents (DAAs) has revolutionized the treatment of those with chronic hepatitis C. Rather than endure a difficult course of therapy that may last 6 to 12 months, treatment of hepatitis C typically lasts 8 to 12 weeks with sustained response or cure rates well over 90%. […] Once viremia has been confirmed, those with HCV who can comply with therapy are offered treatment with DAA therapy. In the past, many populations were excluded from treatment for hepatitis C due to side effects of prior interferon-based therapies. At present, the difficult to treat populations are few with high sustained virologic response (SVR) rates being achieved in those treated with DAAs in cirrhosis patients, HIV/HCV co-infection, renal disease, and transplant populations.

• #15 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life. […] Compared to former IFN-based regimens DAA treatment is highly effective in the majority of the patients. Therapy is not only shorter, but also well tolerated and even most patients with former contraindications to IFN therapy, mainly patients with decompensated cirrhosis or significant comorbidities, can now be treated. […] The introduction of DAA revolutionized the field of antiviral therapy for patients chronically infected with HCV. Antiviral therapy usually consists of at least two antiviral substances from different drug classes with different modes of action. Treatment decisions are based on (sub-)genotype, presence of cirrhosis and response to prior treatments.

• #16 Gilead’s curative hepatitis C therapies

  https://www.gilead.com/stories/gilead-sets-sights-on-hepatitis-c-elimination-as-it-marks-10-years-of-curative-therapies

  Gilead Sets Sights on Hepatitis C Elimination as it Marks 10 Years of Curative Therapies […] Long-time liver specialist Carrie Frenette says she wont ever forget the people she treated for hepatitis C (HCV) before 2013 the year that the Food and Drug Administration (FDA) approved Gilead’s first curative therapy for HCV. […] Since 2013, more curative therapies have become available and have helped revolutionize the care of those living with chronic HCV around the world. Today, 95% or more of those treated are cured, whereas cure rates varied for prior treatments that were available. […] Gilead researchers went on to develop three more curative therapies. In the 10 years since the initial FDA approval and subsequent approvals in other countries, more than 4 million people globally have been treated with Gileads HCV medicines. In total, according to the World Health Organization (WHO), more than 10 million people worldwide have been cured of HCV.

• #17 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel continues to strongly recommend universal DAA treatment for all people with acute or chronic HCV infection (except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy). […] In the current DAA era of hepatitis C treatment, therapy is safe, effective, of relatively short duration, and curative in most people. […] Given the many benefits of virologic cure, including reduced risk of cirrhosis, hepatocellular carcinoma, liver-related mortality, and all-cause mortality, expanded use of DAA treatment and the associated probable cure has the capacity to reduce HCV-related disease burden at individual, national, and potentially global levels. […] Although DAA therapy is curative for most persons, the small percentage of those in whom treatment fails to result in SVR12 require retreatment.

• #18 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. […] Therefore, the panel continues to recommend treatment for all patients with chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy. […] A well-established therapeutic relationship between clinician and patient remains crucial for optimal outcomes with direct-acting antiviral (DAA) therapies. […] The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response.

• #19 Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin

  https://emedicine.medscape.com/article/177792-treatment

  The treatment goal of HCV-infected individuals is the reduction of all-cause mortality and hepatic-associated morbidity (eg, end-stage liver disease, hepatocellular carcinoma) as achieved by virologic cure, with sustained virologic response. […] Hepatitis C has become a curable disease with the use of antiviral agents (95%). […] Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD), in collaboration with the International Antiviral Society-USA (IAS-USA). […] The AASLD/IDSA guidelines previously proposed that because all patients cannot receive treatment immediately upon the approval of new agents, priority should be given to those with the most urgent need. […] The AASLD/IDSA guidelines removed their prioritization tables but continue to strongly recommend treatment for all patients with acute or chronic HCV infection, barring those with shortened life expectancies that cannot be resolved by HCV treatment, liver transplantation, or another directed therapy.

• #20 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Cure of HCV infection also reduces symptoms and mortality from severe extrahepatic manifestations, including cryoglobulinemic vasculitis, a condition affecting 10% to 15% of HCV-infected patients. […] Because of the many benefits associated with successful HCV treatment, clinicians should treat HCV-infected patients with antiviral therapy with the goal of achieving SVR, preferably early in the course of chronic hepatitis C before the development of severe liver disease and other complications. […] Initiating therapy in patients with lower-stage fibrosis augments the benefits of SVR. […] Treatment delay may decrease the benefit of SVR. […] Numerous studies have demonstrated that hepatitis C therapy and the achievement of SVR in this population results in dramatic decreases in hepatic decompensation events, HCC, and liver-related mortality.

• #21 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C virus is treated with all-oral medications. These pills, called antiviral medications, are usually taken once per day. These antiviral medications are extremely good at attacking the virus and preventing it from multiplying. […] Antiviral medications were not the original treatment for hepatitis C. Before 2014, the only treatment for hepatitis C was called interferon and ribavirin, taken as weekly injections under the skin, plus pills. Interferon treatment caused many unpleasant side effects and was not usually successful. Then a new generation of medications became available. These antiviral treatments are extremely successful at curing the virus and have very minimal side effects. […] The purpose of taking antiviral medications for hepatitis C is to: remove (or clear) all the hepatitis C virus from your body permanently, stop or slow down the damage to your liver, reduce the risk of developing cirrhosis (advanced scarring of the liver), reduce the risk of developing liver cancer (hepatocellular carcinoma), reduce the risk of liver failure and the need for a liver transplant.

• #22 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Cure of HCV infection also reduces symptoms and mortality from severe extrahepatic manifestations, including cryoglobulinemic vasculitis, a condition affecting 10% to 15% of HCV-infected patients. […] Because of the many benefits associated with successful HCV treatment, clinicians should treat HCV-infected patients with antiviral therapy with the goal of achieving SVR, preferably early in the course of chronic hepatitis C before the development of severe liver disease and other complications. […] Initiating therapy in patients with lower-stage fibrosis augments the benefits of SVR. […] Treatment delay may decrease the benefit of SVR. […] Numerous studies have demonstrated that hepatitis C therapy and the achievement of SVR in this population results in dramatic decreases in hepatic decompensation events, HCC, and liver-related mortality.

• #23 Hepatitis C treatment for people with HIV | aidsmap

  https://www.aidsmap.com/about-hiv/hepatitis-c-treatment-people-hiv

  Curing hepatitis C halts viral transmission, and studies are starting to show that widespread treatment is reducing new hepatitis C infections. […] Current guidelines recommend that everyone with HIV and HCV co-infection should start hepatitis C treatment with DAAs. […] Treatment is especially urgent if you have moderate or worse liver fibrosis (stage F2 to F4). […] People on antiretroviral treatment for HIV can be successfully treated for hepatitis C at the same time. […] HIV treatment should not be interrupted in order to start hepatitis C treatment. […] The health of your liver should be regularly monitored during HIV and hepatitis C treatment.

• #24 Hepatitis C Medications: A Full List

  https://www.healthline.com/health/hepatitis-c/full-medication-list

  The most common hepatitis C medications are direct-acting antivirals (DAAs). A typical treatment plan involves a combination of two or more DAAs. In some cases, doctors also combine DAAs with ribavirin or interferons. […] Chronic hepatitis C needs treatment with medication. Drugs can help ease symptoms and, in many cases, cure the condition. […] Even if an HCV infection hasn’t caused symptoms yet, treatment is important. This is because medications can lower the risk of complications from hepatitis C, such as liver problems. […] Direct-acting antivirals (DAAs) are the most common treatment for hepatitis C. They’re usually taken as pills. These medications can cure hepatitis C in 90-97% of cases. They work by helping to stop HCV from multiplying. […] DAAs are currently the standard of care for chronic HCV infection. These drugs work by attacking HCV directly.

• #25 Hepatitis C Treatment Options

  https://www.webmd.com/hepatitis/understanding-hepatitis-c-treatment

  Research is moving rapidly on treatments for hep C. As a result, what doctors will recommend for each case may change. […] Elbasvir and grazoprevir (Zepatier): This once-a-day pill treats HCV types 1 and 4. […] Glecaprevir and pibrentasvir (Mavyret): Three pills daily can treat all types of hep C. […] Ledipasvir and sofosbuvir (Harvoni): This once-a-day pill launched a revolution in hep C treatment. It was the first interferon-free med for people with type 1. […] Ombitasvir, paritaprevir, and ritonavir, with dasabuvir (Viekira Pak): Doctors say this treatment works well for people with HCV type 1. […] Sofosbuvir and velpatasvir (Epclusa): This can treat all types of hep C with a single tablet. […] Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi): This can also treat all types of hep C with one tablet that you take each day.

• #26 What are the new drugs for the treatment of hepatitis C?

  https://www.drugs.com/medical-answers/new-drugs-hepatitis-3511306/

  The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir). […] Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). […] Mavyret is used to treat patients 3 years of age and older. Mavyret is also approved for patients 3 years and older with HCV genotype 1 infection, who have previously been treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both. […] Vosevi is indicated for use in the treatment of adult patients. It is used as a re-treatment option in patients who have been previously treated with an NS5A inhibitor-containing regimen (GT1-6), or a regimen containing sofosbuvir without an NS5A inhibitor (GT1a or GT3).

• #27 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  DAAs are not used as single medications but are used in specific combinations to maximize efficacy. […] Current recommendations for HCV treatment are evolving rapidly. […] Treatment of HCV with DAAs now uses multiple medication regimens that are effective against all genotypes; these regimens are called pangenotypic. […] Regimens of sofosbuvir/velpatasvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients. […] Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplantation center. […] Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs.

• #28 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life. […] Compared to former IFN-based regimens DAA treatment is highly effective in the majority of the patients. Therapy is not only shorter, but also well tolerated and even most patients with former contraindications to IFN therapy, mainly patients with decompensated cirrhosis or significant comorbidities, can now be treated. […] The introduction of DAA revolutionized the field of antiviral therapy for patients chronically infected with HCV. Antiviral therapy usually consists of at least two antiviral substances from different drug classes with different modes of action. Treatment decisions are based on (sub-)genotype, presence of cirrhosis and response to prior treatments.

• #29

  https://www.hepatitisaustralia.com/hepatitis-c-cures

  You can take medicine to cure hepatitis C. It works very well for most people. […] The medicines are direct-acting antivirals (or DAAs). They work very well for most people who take them. You’ll need to take one to three tablets for eight to 12 weeks. This will depend on which medicine your doctor gives you. […] Your normal GP can prescribe you the new DAA medicines for hepatitis C. […] The new DAA medicines have far less side effects than older medicines. The side effects are also less common and often less serious. […] In Australia, we use these DAA medicines to cure hepatitis C: Epclusa (sofosbuvir + velpatasvir), Maviret (glecaprevir/pibrentasvir), Vosevi (sofosbuvir + velpatasvir + voxilaprevir). We only use this one if other DAA medicine has not worked. […] If the medicine has worked, you no longer have the virus. Your doctor will order a test at least 12 weeks after you finish taking the medicine. This test will tell you if you still have the virus. It’s a good idea to have this final test to make sure you are cured, and not just assume it. […] If you do get hepatitis C again, you will be able to take medicine again to get rid of the virus.

• #30 Hepatitis C Treatment Options

  https://www.webmd.com/hepatitis/understanding-hepatitis-c-treatment

  Research is moving rapidly on treatments for hep C. As a result, what doctors will recommend for each case may change. […] Elbasvir and grazoprevir (Zepatier): This once-a-day pill treats HCV types 1 and 4. […] Glecaprevir and pibrentasvir (Mavyret): Three pills daily can treat all types of hep C. […] Ledipasvir and sofosbuvir (Harvoni): This once-a-day pill launched a revolution in hep C treatment. It was the first interferon-free med for people with type 1. […] Ombitasvir, paritaprevir, and ritonavir, with dasabuvir (Viekira Pak): Doctors say this treatment works well for people with HCV type 1. […] Sofosbuvir and velpatasvir (Epclusa): This can treat all types of hep C with a single tablet. […] Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi): This can also treat all types of hep C with one tablet that you take each day.

• #31 Initial Treatment of Adults with HCV Infection | HCV Guidance

  https://www.hcvguidelines.org/treatment-naive

  Initial treatment of HCV infection includes patients with chronic hepatitis C who have not been previously treated with interferon, peginterferon, ribavirin, or any HCV direct-acting antiviral (DAA) agent, whether investigational, or US Food and Drug Administration (FDA) approved. […] Simplification of the treatment regimen may expand the number of healthcare professionals who prescribe antiviral therapy and increase the number of persons treated. This would align with the National Academies of Science, Engineering, and Medicine strategy to reduce cases of chronic HCV infection by 90% by 2030 (NAS, 2017). […] Recommended and alternative regimens are listed by pan-genotypic activity and in order of level of evidence. When several regimens are at the same recommendation level, they are listed in alphabetical order. Regimen choice should be determined based on patient-specific data, including drug-drug interactions.

• #32 Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults – UpToDate

  https://www.uptodate.com/contents/management-of-chronic-hepatitis-c-virus-infection-initial-antiviral-therapy-in-adults

  Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. The acute process is self-limited, rarely causes hepatic failure, and usually leads to chronic infection. Chronic HCV infection often follows a progressive course over many years and can ultimately result in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. […] Successful antiviral treatment of chronic HCV infection halts the progression of liver disease and is associated with improvement in liver-related morbidity and mortality. This topic will review the antiviral selection and administration for initial therapy of chronic HCV infection. […] Our recommendations are generally consistent with joint guidelines on HCV management from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), which can be accessed at www.hcvguidelines.org.

• #33 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  All different recommended regimens achieve SVR rates of more than 95% if administered correctly. […] The pangenotypic drug combinations sofosbuvir/velpatasvir and glecaprevir/pibrentasvir show high antiviral efficacy against all HCV genotypes. Treatment duration differs from 8 weeks for glecaprevir/pibrentasvir in noncirrhotic treatment-naive patients to 12 weeks for patients with liver cirrhosis or 16 weeks for GT 3 patients with liver cirrhosis and/or prior treatment failure. […] In most of the cases treatment is well tolerated, and the coadministration of RBV is not necessary. […] After failure of DAA treatment, the development of RAS is very likely. […] Currently, the only approved drug combination for the retreatment of patients with prior DAA failure is the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX). This combination is not only well tolerated, but also highly effective, and SVR rates 95% can be achieved in pretreated patients independently from the initial treatment regimen.

• #34 Hepatitis C Medications: A Full List

  https://www.healthline.com/health/hepatitis-c/full-medication-list

  DAAs can cure HCV in more than 90% of cases with 8-24 weeks of treatment. […] Ribavirin works by stopping viruses from replicating and spreading. It’s an oral medication that comes in several strengths. […] Ribavirin on its own is not an effective treatment option for HCV. Doctors often use it in combination with other drugs to help them be more effective. […] These days, interferons are not commonly used to treat HCV. The newer treatments listed above are typically used instead. This is because interferons can cause a lot of side effects and are not as effective for treating chronic HCV infection. […] The current standard of care for hepatitis C involves direct-acting antivirals because they directly attack the virus and have a tolerable side effect profile compared with older treatment options. […] The FDA approved glecaprevir-pibrentasvir (Mavyret) in 2017 for hepatitis C. Doctors can use it to treat any HCV genotype. […] Glecaprevir-pibrentasvir (Mavyret) can treat hepatitis C in 8 weeks in people without cirrhosis. You typically need to take other hepatitis C medications for 12 weeks.

• #35 What are the new drugs for the treatment of hepatitis C?

  https://www.drugs.com/medical-answers/new-drugs-hepatitis-3511306/

  Epclusa is approved for use in adults and children 3 years of age and older. Epclusa is also approved in adults and children 3 years of age and older for the treatment of HCV genotype 1, 2, 3, 4, 5 or 6 in patients with decompensated cirrhosis (for use in combination with ribavirin). […] Epclusa has a 98% overall cure rate in all 6 of the main types of hepatitis C in patients without cirrhosis (a serious liver disease) or with compensated cirrhosis (mild or no symptoms). […] Epclusa (sofosbuvir and velpatasvir) is given as a single daily pill for 12 weeks duration. With advanced liver disease (decompensated cirrhosis, Child-Pugh B or C), it is combined with ribavirin, also for 12 weeks. If Epclusa is prescribed with ribavirin, follow your doctor’s recommendations for ribavirin dosing. […] Does Mavyret cure hep C (HCV)? What is the success rate?

• #36 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel continues to strongly recommend universal DAA treatment for all people with acute or chronic HCV infection (except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy). […] In the current DAA era of hepatitis C treatment, therapy is safe, effective, of relatively short duration, and curative in most people. […] Given the many benefits of virologic cure, including reduced risk of cirrhosis, hepatocellular carcinoma, liver-related mortality, and all-cause mortality, expanded use of DAA treatment and the associated probable cure has the capacity to reduce HCV-related disease burden at individual, national, and potentially global levels. […] Although DAA therapy is curative for most persons, the small percentage of those in whom treatment fails to result in SVR12 require retreatment.

• #37 Hepatitis C You Later! | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-c-you-later

  Direct-acting antivirals have revolutionized treatment of HCV. […] They have allowed us to expand the donor pool to include HCV-positive donors for HCV-negative recipients, and treat recipients post-transplantation with extremely high rates of cure. […] Simplified treatment in HCV without cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks). […] Simplified treatment for HCV with compensated cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks, genotype 3 requires NS5A resistance testing). […] Ledipasvir/sofosbuvir (genotypes 1,4,5,6) and sofosbuvir/velpatasvir (pan-genotypic, NS5A resistance testing in genotype 3) are preferred regimens in decompensated cirrhosis. […] DAAs have revolutionized the management of HCV, and have cure rates well above 95%.

• #38 Hepatitis C: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/1200/p626.html

  Screening recommendations and treatment guidelines for hepatitis C virus (HCV) infection have been updated. […] For treatment-naive adults without cirrhosis or with compensated cirrhosis, a simplified treatment regimen consisting of eight weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvir results in greater than 95% cure rates. […] A sustained virologic response is associated with lower all-cause mortality and improves hepatic and extrahepatic manifestations, cognitive function, physical health, work productivity, and quality of life. […] Adults with HCV infection who meet criteria for treatment with a simplified regimen should be treated with eight weeks of glecaprevir/pibrentasvir (Mavyret) or 12 weeks of sofosbuvir/velpatasvir (Epclusa), regardless of the HCV genotype.

• #39 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C treatment regimens have extremely high success rates. There is roughly a 95 percent cure (SVR) rate overall. […] All patients with hepatitis C should be evaluated for treatment, including patients who: have cirrhosis, use drugs, drink alcohol, are homeless, have other medical problems. […] The medications will usually cause a very big drop in the viral load within the first two weeks. Some patients will see their viral load become undetectable very early, such as by the fourth week. For other patients, it can take longer until their viral load becomes undetectable. […] Relapse means the medicine was able to lower the hepatitis C viral load to the undetectable level for a time, but then the viral load increased again. Re-treatment options should then be discussed with the provider.

• #40 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  All different recommended regimens achieve SVR rates of more than 95% if administered correctly. […] The pangenotypic drug combinations sofosbuvir/velpatasvir and glecaprevir/pibrentasvir show high antiviral efficacy against all HCV genotypes. Treatment duration differs from 8 weeks for glecaprevir/pibrentasvir in noncirrhotic treatment-naive patients to 12 weeks for patients with liver cirrhosis or 16 weeks for GT 3 patients with liver cirrhosis and/or prior treatment failure. […] In most of the cases treatment is well tolerated, and the coadministration of RBV is not necessary. […] After failure of DAA treatment, the development of RAS is very likely. […] Currently, the only approved drug combination for the retreatment of patients with prior DAA failure is the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX). This combination is not only well tolerated, but also highly effective, and SVR rates 95% can be achieved in pretreated patients independently from the initial treatment regimen.

• #41 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life. […] Compared to former IFN-based regimens DAA treatment is highly effective in the majority of the patients. Therapy is not only shorter, but also well tolerated and even most patients with former contraindications to IFN therapy, mainly patients with decompensated cirrhosis or significant comorbidities, can now be treated. […] The introduction of DAA revolutionized the field of antiviral therapy for patients chronically infected with HCV. Antiviral therapy usually consists of at least two antiviral substances from different drug classes with different modes of action. Treatment decisions are based on (sub-)genotype, presence of cirrhosis and response to prior treatments.

• #42 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Treatment is recommended for all patients with acute or chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. […] The proximate goal of HCV therapy is SVR (virologic cure), defined as the continued absence of detectable HCV RNA for at least 12 weeks after completion of therapy. […] Patients who are cured of their HCV infection experience numerous health benefits, including a decrease in liver inflammation as reflected by improved aminotransferase levels (ie, alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), and a reduction in the rate of liver fibrosis progression. […] Among HCV-infected persons, SVR is associated with a 70% reduction in the risk of liver cancer (hepatocellular carcinoma [HCC]), and a 90% reduction in the risk of liver-related mortality and liver transplantation.

• #43 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life. […] Compared to former IFN-based regimens DAA treatment is highly effective in the majority of the patients. Therapy is not only shorter, but also well tolerated and even most patients with former contraindications to IFN therapy, mainly patients with decompensated cirrhosis or significant comorbidities, can now be treated. […] The introduction of DAA revolutionized the field of antiviral therapy for patients chronically infected with HCV. Antiviral therapy usually consists of at least two antiviral substances from different drug classes with different modes of action. Treatment decisions are based on (sub-)genotype, presence of cirrhosis and response to prior treatments.

• #44 Initial Treatment of Adults with HCV Infection | HCV Guidance

  https://www.hcvguidelines.org/treatment-naive

  Patients receiving antiviral therapy require careful pretreatment assessment for comorbidities that may influence treatment response or regimen selection. All patients should have access to an HCV care provider during treatment, although preset clinic visits and/or blood tests depend on the treatment regimen and may not be required for all regimens/patients. […] Rarely, genotyping assays may indicate the presence of a mixed infection (eg, genotypes 1a and 2). Treatment data for mixed genotypes with DAAs are sparse but utilization of a pangenotypic regimen is recommended in this circumstance (Chiu, 2020).

• #45 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  DAAs are not used as single medications but are used in specific combinations to maximize efficacy. […] Current recommendations for HCV treatment are evolving rapidly. […] Treatment of HCV with DAAs now uses multiple medication regimens that are effective against all genotypes; these regimens are called pangenotypic. […] Regimens of sofosbuvir/velpatasvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients. […] Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplantation center. […] Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs.

• #46 Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin

  https://emedicine.medscape.com/article/177792-treatment

  With the exception of pregnant women, the World Health Organization recommends treatment be offered to all individuals aged 12 years or older diagnosed with HCV, regardless of their disease stage. […] Initiating treatment earlier for patients with lower stage fibrosis may extend the benefits of sustained virologic response (SVR). […] Treatment of chronic HCV infection has two goals. The first is to achieve sustained eradication of HCV (ie, SVR), which is defined as the persistent absence of HCV RNA in serum 12 weeks after completing antiviral treatment. The second goal is to prevent progression to cirrhosis, HCC, and decompensated liver disease requiring liver transplantation. […] Antiviral therapy for chronic hepatitis C should be determined on a case-by-case basis. However, treatment is widely recommended for patients with elevated serum alanine aminotransferase (ALT) levels who meet the following criteria: Age older than 18 years, Positive HCV antibody and serum HCV RNA test results, Compensated liver disease (eg, no hepatic encephalopathy or ascites), Acceptable hematologic and biochemical indices, Willingness to be treated and to adhere to treatment requirements, No contraindications for treatment.

• #47

  https://www.nhs.uk/conditions/hepatitis-c/treatment/

  Hepatitis C can often be treated successfully by taking medicines for several weeks. […] Treatment for chronic hepatitis C (those infected for 6 months or more) involves: tablets to fight the virus, a test to see if your liver is damaged, lifestyle changes to prevent further damage. […] You’ll be offered the medicine most appropriate for your type of hepatitis C. […] During treatment, you should have blood tests to check that your medicine is working. […] At the end of your treatment, you’ll have a blood test to see if the virus has been cleared and a second blood test 12 or 24 weeks after treatment has stopped. […] If both tests show no sign of the virus, this means treatment has been successful. […] Hepatitis C is treated using direct-acting antiviral (DAA) tablets. […] DAA tablets are the safest and most effective medicines for treating hepatitis C.

• #48

  https://www2.hse.ie/conditions/hepatitis-c/treatment/

  They’re effective at clearing the infection in more than 95% of people. […] You take the tablets for 8 to 12 weeks. The length of treatment depends on the type of hepatitis C you have. […] Direct-acting antivirals (DAAs) cure over 9 in 10 patients with hepatitis C. […] You need to complete the full course of treatment to clear the hepatitis C virus from your body. […] If your treatment is successful, you do not have any protection against another hepatitis C infection. […] Some hepatitis C medicines have not been tested in pregnancy. […] You should not become pregnant while taking treatment as it could be harmful to unborn babies. […] By not getting treatment you increase your chances of developing serious liver disease, cirrhosis, liver cancer, liver failure or end stage liver disease.

• #49 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Treatment is successful when the viral load drops to undetectable levels, which means the virus cannot be detected in the bloodstream at all. The viral load becomes undetectable during treatment and remains undetected after treatment has ended. If there is still no detectable virus in the blood 12 weeks after the end of the treatment, the treatment was successful. This is called a Sustained Virologic Response (SVR). […] A patient who has achieved an SVR is considered to be cured of the hepatitis C virus. […] Since 2014, multiple different antiviral treatments for hepatitis C have been developed. With the many options now available, often there is more than one good choice for a patient. […] Treatment is usually 8-12 weeks long but can be as much as 16 weeks long in certain situations. Some patients with more damage to their liver may require 24 weeks of treatment, but this is uncommon. The duration depends on the medication, and specific HCV factors in particular patients.

• #50 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  Renal excretion is the main elimination pathway of the NS5B polymerase inhibitor sofosbuvir and its metabolites. […] Treatment of patients with decompensated cirrhosis (Child-Pugh Score B/C (CPS B/C)) is limited to regimens containing sofosbuvir and NS5A inhibitors. […] Many studies and real-world data have shown that IFN-free antiviral therapy is safe in patients with advanced liver disease. […] The efficacy of sofosbuvir/ledipasvir plus RBV was studied in the SOLAR-1 and -2 study. […] The impact of DAA treatment on hepatocellular carcinoma (HCC) incidence, recurrence and tumor aggressiveness in patients with chronic HCV infection has been intensively discussed over the last 2 years. […] After liver transplantation reinfection of the graft leads to fast development of liver fibrosis, and consequently the risks of organ dysfunction and graft loss are significantly increased. Thus, antiviral treatment is essential to preserve liver function and ensure transplant survival.

• #51 Hepatitis C You Later! | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-c-you-later

  Direct-acting antivirals have revolutionized treatment of HCV. […] They have allowed us to expand the donor pool to include HCV-positive donors for HCV-negative recipients, and treat recipients post-transplantation with extremely high rates of cure. […] Simplified treatment in HCV without cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks). […] Simplified treatment for HCV with compensated cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks, genotype 3 requires NS5A resistance testing). […] Ledipasvir/sofosbuvir (genotypes 1,4,5,6) and sofosbuvir/velpatasvir (pan-genotypic, NS5A resistance testing in genotype 3) are preferred regimens in decompensated cirrhosis. […] DAAs have revolutionized the management of HCV, and have cure rates well above 95%.

• #52 Hepatitis C You Later! | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-c-you-later

  Direct-acting antivirals have revolutionized treatment of HCV. […] They have allowed us to expand the donor pool to include HCV-positive donors for HCV-negative recipients, and treat recipients post-transplantation with extremely high rates of cure. […] Simplified treatment in HCV without cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks). […] Simplified treatment for HCV with compensated cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks, genotype 3 requires NS5A resistance testing). […] Ledipasvir/sofosbuvir (genotypes 1,4,5,6) and sofosbuvir/velpatasvir (pan-genotypic, NS5A resistance testing in genotype 3) are preferred regimens in decompensated cirrhosis. […] DAAs have revolutionized the management of HCV, and have cure rates well above 95%.

• #53 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  DAAs are not used as single medications but are used in specific combinations to maximize efficacy. […] Current recommendations for HCV treatment are evolving rapidly. […] Treatment of HCV with DAAs now uses multiple medication regimens that are effective against all genotypes; these regimens are called pangenotypic. […] Regimens of sofosbuvir/velpatasvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients. […] Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplantation center. […] Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs.

• #54 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  DAAs are not used as single medications but are used in specific combinations to maximize efficacy. […] Current recommendations for HCV treatment are evolving rapidly. […] Treatment of HCV with DAAs now uses multiple medication regimens that are effective against all genotypes; these regimens are called pangenotypic. […] Regimens of sofosbuvir/velpatasvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients. […] Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplantation center. […] Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs.

• #55 Hepatitis C Virus/HIV Coinfection | NIH

  https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-c-virus-hcv

  All people with HIV should be screened for hepatitis C virus (HCV) infection (AIII). Patients at high risk of HCV infection should be screened annually and whenever incident HCV infection is suspected (AIII). […] Antiretroviral therapy (ART) may slow the progression of liver disease by preserving or restoring immune function and reducing HIV-related immune activation and inflammation. For most patients with HCV/HIV coinfection, including those with cirrhosis, the benefits of ART outweigh concerns regarding drug-induced liver injury. Therefore, ART should be initiated in all patients with HCV/HIV coinfection, regardless of CD4 T lymphocyte cell count (AI). […] Initial antiretroviral (ARV) regimens that are recommended for most patients with HCV/HIV coinfection are the same as those recommended for people with HIV who do not have HCV infection. However, when treatment for both HIV and HCV is indicated, the ARV and HCV treatment regimens should be selected with special consideration for potential drug-drug interactions and overlapping toxicities (AIII).

• #56 Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin

  https://emedicine.medscape.com/article/177792-treatment

  The American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) define decompensated cirrhosis as moderate or severe hepatic impairment. […] Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at risk for accelerated liver fibrosis and should usually be offered antiviral treatment. […] Coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV), in the absence of human immunodeficiency virus (HIV) infection, is relatively uncommon in the United States, and optimal treatment regimens have not been established. […] Recurrent hepatitis C viral (HCV) infection is universal after liver transplantation, can lead to cirrhosis in 30% of patients within 5 years, and is emerging as the most common cause of retransplantation in the United States.

• #57 Hepatitis C treatment for people with HIV | aidsmap

  https://www.aidsmap.com/about-hiv/hepatitis-c-treatment-people-hiv

  Curing hepatitis C halts viral transmission, and studies are starting to show that widespread treatment is reducing new hepatitis C infections. […] Current guidelines recommend that everyone with HIV and HCV co-infection should start hepatitis C treatment with DAAs. […] Treatment is especially urgent if you have moderate or worse liver fibrosis (stage F2 to F4). […] People on antiretroviral treatment for HIV can be successfully treated for hepatitis C at the same time. […] HIV treatment should not be interrupted in order to start hepatitis C treatment. […] The health of your liver should be regularly monitored during HIV and hepatitis C treatment.

• #58 Hepatitis C treatment for people with HIV | aidsmap

  https://www.aidsmap.com/about-hiv/hepatitis-c-treatment-people-hiv

  Direct-acting antiviral (DAA) medicines can cure most people with hepatitis C regardless of age, sex, race or HIV status. […] Effective direct-acting antiviral or 'DAA’ medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult to treat, including those with HIV co-infection, severe liver disease, prior treatment failure and people who use drugs. […] The newest DAAs cure more than 90% of people with chronic hepatitis C. […] With the new drugs, however, many experts now recommend that everyone with hepatitis C should be treated, regardless of liver disease severity, and say there is little reason to wait. […] Treatment is more effective when people have not yet developed severe liver disease.

• #59 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  Renal excretion is the main elimination pathway of the NS5B polymerase inhibitor sofosbuvir and its metabolites. […] Treatment of patients with decompensated cirrhosis (Child-Pugh Score B/C (CPS B/C)) is limited to regimens containing sofosbuvir and NS5A inhibitors. […] Many studies and real-world data have shown that IFN-free antiviral therapy is safe in patients with advanced liver disease. […] The efficacy of sofosbuvir/ledipasvir plus RBV was studied in the SOLAR-1 and -2 study. […] The impact of DAA treatment on hepatocellular carcinoma (HCC) incidence, recurrence and tumor aggressiveness in patients with chronic HCV infection has been intensively discussed over the last 2 years. […] After liver transplantation reinfection of the graft leads to fast development of liver fibrosis, and consequently the risks of organ dysfunction and graft loss are significantly increased. Thus, antiviral treatment is essential to preserve liver function and ensure transplant survival.

• #60 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits. […] Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 to the June 2021 approval of 2 pangenotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years. […] Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation. […] Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs.

• #61 Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin

  https://emedicine.medscape.com/article/177792-treatment

  The American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) define decompensated cirrhosis as moderate or severe hepatic impairment. […] Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at risk for accelerated liver fibrosis and should usually be offered antiviral treatment. […] Coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV), in the absence of human immunodeficiency virus (HIV) infection, is relatively uncommon in the United States, and optimal treatment regimens have not been established. […] Recurrent hepatitis C viral (HCV) infection is universal after liver transplantation, can lead to cirrhosis in 30% of patients within 5 years, and is emerging as the most common cause of retransplantation in the United States.

• #62 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Effective HCV therapy prior to transplantation resulting in SVR (virologic cure) prevents HCV recurrence post transplantation. […] Treatment of established HCV infection post transplantation also yields substantial improvements in patient and graft survival. […] Given the clinical complexity (including drug-drug interactions and the need for close monitoring), patients with a liver transplant should be treated by physicians with experience in treating this population. […] Successful treatment of HCV-infected persons at greatest risk for transmission represents a formidable tool to help stop HCV transmission in those who continue to engage in high-risk behaviors. […] Injection drug use (IDU) is the most common risk factor for HCV infection in the United States and Europe, with an HCV seroprevalence rate of 10% to 70%.

• #63 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits. […] Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 to the June 2021 approval of 2 pangenotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years. […] Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation. […] Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs.

• #64 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  Renal excretion is the main elimination pathway of the NS5B polymerase inhibitor sofosbuvir and its metabolites. […] Treatment of patients with decompensated cirrhosis (Child-Pugh Score B/C (CPS B/C)) is limited to regimens containing sofosbuvir and NS5A inhibitors. […] Many studies and real-world data have shown that IFN-free antiviral therapy is safe in patients with advanced liver disease. […] The efficacy of sofosbuvir/ledipasvir plus RBV was studied in the SOLAR-1 and -2 study. […] The impact of DAA treatment on hepatocellular carcinoma (HCC) incidence, recurrence and tumor aggressiveness in patients with chronic HCV infection has been intensively discussed over the last 2 years. […] After liver transplantation reinfection of the graft leads to fast development of liver fibrosis, and consequently the risks of organ dysfunction and graft loss are significantly increased. Thus, antiviral treatment is essential to preserve liver function and ensure transplant survival.

• #65 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  DAAs are not used as single medications but are used in specific combinations to maximize efficacy. […] Current recommendations for HCV treatment are evolving rapidly. […] Treatment of HCV with DAAs now uses multiple medication regimens that are effective against all genotypes; these regimens are called pangenotypic. […] Regimens of sofosbuvir/velpatasvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients. […] Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplantation center. […] Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs.

• #66 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  All different recommended regimens achieve SVR rates of more than 95% if administered correctly. […] The pangenotypic drug combinations sofosbuvir/velpatasvir and glecaprevir/pibrentasvir show high antiviral efficacy against all HCV genotypes. Treatment duration differs from 8 weeks for glecaprevir/pibrentasvir in noncirrhotic treatment-naive patients to 12 weeks for patients with liver cirrhosis or 16 weeks for GT 3 patients with liver cirrhosis and/or prior treatment failure. […] In most of the cases treatment is well tolerated, and the coadministration of RBV is not necessary. […] After failure of DAA treatment, the development of RAS is very likely. […] Currently, the only approved drug combination for the retreatment of patients with prior DAA failure is the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX). This combination is not only well tolerated, but also highly effective, and SVR rates 95% can be achieved in pretreated patients independently from the initial treatment regimen.

• #67 Hepatitis C, Chronic – Hepatic and Biliary Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-c-chronic

  Patients with chronic hepatitis B or evidence of prior hepatitis B should be monitored for reactivation during and after HCV treatment, and HBV antiviral therapy should be considered during the course of HCV treatment. […] New treatments can permanently eliminate HCV RNA in 95% of patients. […] Patients with decompensated cirrhosis should be treated by hepatologists, and regimens containing protease inhibitors should not be used.

• #68 Hepatitis C Virus/HIV Coinfection | NIH

  https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-c-virus-hcv

  All patients with HCV/HIV coinfection should be evaluated for HCV therapy, which includes assessing their liver fibrosis stage to guide the duration of therapy and to predict subsequent risk of hepatocellular carcinoma and liver disease complications (AIII). […] Patients with chronic HCV/HIV coinfection should be screened for active and prior hepatitis B virus (HBV) infection by testing for the presence of hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B surface (HBsAb) and hepatitis B core (HBcAb; total or Immunoglobulin G). Persons who are not immune to HBV infection (HBsAb negative) should receive anti-HBV vaccination (AIII). […] HBV reactivation has been observed in people with HBV infection during HCV treatment with direct-acting antivirals. Accordingly, before initiating HCV therapy, patients with HCV/HIV coinfection and active HBV infection (HBsAg positive) should receive ART that includes two agents with anti-HBV activity (AIII).

• #69 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  In patients with hepatitis B virus (HBV) co-infection, HBV DNA is usually low although fluctuation cannot be excluded whereas HCV RNA is present and the driver of hepatic inflammation. […] Former antiviral regimens containing protease inhibitors like boceprevir or telaprevir combined with peginterferon alfa had serious side effects. […] When looking at more modern regimens like glecaprevir/pibrentasvir, elbasvir/grazoprevir and velpatasvir/sofosbuvir voxilaprevir, the potential for side effects does not seem to turn the balance in HCV therapy anymore. […] DDI can either have pharmacodynamic or pharmacokinetic impact or both on all involved substances. […] However, theoretical potential for interactions does not always result in clinically relevant DDI. […] With the availability of DAA, high rates of viral eradication can be realized while treatment is overall safe. DDI need to be considered but are well manageable.

• #70 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C treatment regimens have extremely high success rates. There is roughly a 95 percent cure (SVR) rate overall. […] All patients with hepatitis C should be evaluated for treatment, including patients who: have cirrhosis, use drugs, drink alcohol, are homeless, have other medical problems. […] The medications will usually cause a very big drop in the viral load within the first two weeks. Some patients will see their viral load become undetectable very early, such as by the fourth week. For other patients, it can take longer until their viral load becomes undetectable. […] Relapse means the medicine was able to lower the hepatitis C viral load to the undetectable level for a time, but then the viral load increased again. Re-treatment options should then be discussed with the provider.

• #71 Harvoni Fact Sheet – Treatment Action Group

  https://www.treatmentactiongroup.org/publication/harvoni-fact-sheet/

  The goal of hepatitis C virus (HCV) treatment is a cure (when there is no hepatitis C virus in a person’s bloodstream at least 12 weeks after treatment is finished). […] Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. […] Harvoni is taken once daily, with or without food, for 8 to 24 weeks. Treatment length depends on HCV treatment history, whether a person has cirrhosis, and the amount of hepatitis C virus in a person’s bloodstream (called HCV RNA or viral load). […] The most important thing a person can do to be cured is not to miss taking doses of HCV treatment—this is called adherence. Adherence lowers the risk for drug resistance. […] Each day, HCV makes billions of copies of itself. Some of these copies are not exactly the same as the original virus. They may have changes (called mutations) that can stop hepatitis C drugs from working.

• #72 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  All different recommended regimens achieve SVR rates of more than 95% if administered correctly. […] The pangenotypic drug combinations sofosbuvir/velpatasvir and glecaprevir/pibrentasvir show high antiviral efficacy against all HCV genotypes. Treatment duration differs from 8 weeks for glecaprevir/pibrentasvir in noncirrhotic treatment-naive patients to 12 weeks for patients with liver cirrhosis or 16 weeks for GT 3 patients with liver cirrhosis and/or prior treatment failure. […] In most of the cases treatment is well tolerated, and the coadministration of RBV is not necessary. […] After failure of DAA treatment, the development of RAS is very likely. […] Currently, the only approved drug combination for the retreatment of patients with prior DAA failure is the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX). This combination is not only well tolerated, but also highly effective, and SVR rates 95% can be achieved in pretreated patients independently from the initial treatment regimen.

• #73 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  Updated retreatment recommendations focus on DAA treatment failures, specifically, sofosbuvir-based regimen failure; glecaprevir/pibrentasvir failure; and multiple DAA failure, including sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir plus glecaprevir/pibrentasvir. […] Treatment-naive persons living with HIV and HCV (without cirrhosis or with compensated cirrhosis) are newly eligible for DAA therapy using a simplified treatment algorithm. […] The Guidance Panel reiterates the recommendation that persons with confirmed acute HCV infection (HCV RNA-positive) should be treated the same as those with chronic HCV infection without awaiting possible spontaneous clearance (ie, a test-and-treat approach). […] Treatment recommendations during pregnancy are largely unchanged from the previous update.

• #74 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  All different recommended regimens achieve SVR rates of more than 95% if administered correctly. […] The pangenotypic drug combinations sofosbuvir/velpatasvir and glecaprevir/pibrentasvir show high antiviral efficacy against all HCV genotypes. Treatment duration differs from 8 weeks for glecaprevir/pibrentasvir in noncirrhotic treatment-naive patients to 12 weeks for patients with liver cirrhosis or 16 weeks for GT 3 patients with liver cirrhosis and/or prior treatment failure. […] In most of the cases treatment is well tolerated, and the coadministration of RBV is not necessary. […] After failure of DAA treatment, the development of RAS is very likely. […] Currently, the only approved drug combination for the retreatment of patients with prior DAA failure is the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX). This combination is not only well tolerated, but also highly effective, and SVR rates 95% can be achieved in pretreated patients independently from the initial treatment regimen.

• #75 Hepatitis C Medications: An Overview for Patients – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/products/treatment-update.asp

  Hepatitis C antivirals have very mild or no side effects. Some of the side effects may be: Nausea, Fatigue, Headache, Disturbed sleep (insomnia). […] Patients sometimes ask whether there are ways to treat hepatitis C other than taking medicines. Currently, there are no vaccines to prevent hepatitis C. Once a person is infected, the only way to treat it is with prescribed antiviral medications. […] A transplant provides a new working liver, but a transplant does not get rid of the hepatitis C virus in the patient. Patients with a liver transplant still need antiviral medication to cure their virus.

• #76 MAVYRET Hep C Treatment Information ­- Official Site

  https://www.mavyret.com/hep-c-treatment

  Do not take MAVYRET if you have certain liver problems. […] The most common side effects of MAVYRET are headache and tiredness. […] In people who had or have advanced liver problems before starting treatment with MAVYRET, there is a rare risk of worsening liver problems, liver failure, and death.

• #77 MAVYRET Hep C Treatment Information ­- Official Site

  https://www.mavyret.com/hep-c-treatment

  Danny, CURED* with MAVYRET. […] Cure means no hep C virus found in the blood 3 months after treatment ends. Individual results may vary. […] Studies showed cure rates vary from 95%99%, for those new to treatment. […] MAVYRET is a combination of 2 medicines, glecaprevir and pibrentasvir. Together, they stop the hep C virus from multiplying. MAVYRET stops hep C and CURES* it for most people. […] MAVYRET is a prescription medicine used to treat adults and children 3 years of age and older with chronic (lasting a long time) hepatitis C virus (hep C): […] Hepatitis B virus (hep B) reactivation: Before starting treatment with MAVYRET, your doctor will do blood tests to check for hep B infection. If you have ever had hep B infection, hep B could become active again during or after treatment for hep C with MAVYRET. Hep B that becomes active again (called reactivation) may cause serious liver problems, including liver failure and death. Your doctor will monitor you if you are at risk for hep B reactivation during treatment and after you stop taking MAVYRET.

• #78 Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6616049/

  In patients with hepatitis B virus (HBV) co-infection, HBV DNA is usually low although fluctuation cannot be excluded whereas HCV RNA is present and the driver of hepatic inflammation. […] Former antiviral regimens containing protease inhibitors like boceprevir or telaprevir combined with peginterferon alfa had serious side effects. […] When looking at more modern regimens like glecaprevir/pibrentasvir, elbasvir/grazoprevir and velpatasvir/sofosbuvir voxilaprevir, the potential for side effects does not seem to turn the balance in HCV therapy anymore. […] DDI can either have pharmacodynamic or pharmacokinetic impact or both on all involved substances. […] However, theoretical potential for interactions does not always result in clinically relevant DDI. […] With the availability of DAA, high rates of viral eradication can be realized while treatment is overall safe. DDI need to be considered but are well manageable.

• #79 Treatment for Hepatitis C (HCV) – American Liver Foundation

  https://liverfoundation.org/liver-diseases/viral-hepatitis/hepatitis-c/treating-hepatitis-c/

  The purpose of using medications to treat Hepatitis C is to: Clear the Hepatitis C virus from your bloodstream, Slow down progression of inflammation and scarring of your liver, Reduce the chances of developing cirrhosis and liver cancer. […] Proper adherence to Hepatitis C therapy will increase your chance of being cured and decrease the long-term complications of Hepatitis C. […] The goal of treatment is to have an SVR. This is when you are considered cured. Taking your medication as prescribed will increase your chance of being cured and decrease the long-term complications of Hepatitis C. […] Its important to tell your healthcare provider if you: Have other medical conditions, including liver problems not due to HCV, Take other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

• #80 Hepatitis C – Providers

  https://www.longbeach.gov/health/diseases-and-condition/information-on/hepatitis-c/hepatitis-c—providers/

  Antiviral treatment (Direct Antiviral Agent – DAAs) is available for treating hepatitis C virus. This medication can cure most cases of hepatitis C. Medications are prescribed depending on the genotype, viral load, and presence of any liver damage. It consists of oral pills taken daily for 8-12 weeks. […] For more information on treatments available for hepatitis C, please visit CDC: Clinical Management and Treatment and HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. […] Yes, according to World Health Organization (WHO) Around 30% (15-45%) of infected persons spontaneously clear the virus within 6 months of infection without any treatment. Although this is the case, all patients with acute hepatitis C (with exception of pregnant persons and children under the age of 3) should be treated for their infection instead of waiting for spontaneous clearance of the virus, especially if the patient engages in any high-risk behavior such as injection drug use.

• #81 Clinical Care of Hepatitis C | Hepatitis C | CDC

  https://www.cdc.gov/hepatitis-c/hcp/clinical-care/index.html

  Hepatitis C can be cured in more than 95% of cases with just 8-12 weeks of well-tolerated oral-only treatment with direct-acting antiviral (DAA) agents. […] Curative DAA treatment is recommended for essentially everyone with hepatitis C. […] Available therapies can cure more than 95% of people infected with HCV within 812 weeks of therapy. […] Except for pregnant patients and children under 3, clinicians should treat people with detectable HCV RNA in their blood with oral DAA therapy. There is no need to wait for potential spontaneous viral resolution. […] DAA therapies are not approved for pregnant patients and children under 3. […] Your patient is considered cured of hepatitis C if there is no detectable HCV RNA after 12 weeks of treatment. This indicates they have had a sustained virologic response to therapy.

• #82 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  Updated retreatment recommendations focus on DAA treatment failures, specifically, sofosbuvir-based regimen failure; glecaprevir/pibrentasvir failure; and multiple DAA failure, including sofosbuvir/velpatasvir/voxilaprevir or sofosbuvir plus glecaprevir/pibrentasvir. […] Treatment-naive persons living with HIV and HCV (without cirrhosis or with compensated cirrhosis) are newly eligible for DAA therapy using a simplified treatment algorithm. […] The Guidance Panel reiterates the recommendation that persons with confirmed acute HCV infection (HCV RNA-positive) should be treated the same as those with chronic HCV infection without awaiting possible spontaneous clearance (ie, a test-and-treat approach). […] Treatment recommendations during pregnancy are largely unchanged from the previous update.

• #83 Hepatitis C Treatment Considerations – Viral Hepatitis and Liver Disease

  https://www.hepatitis.va.gov/hcv/treatment/hcv-treatment-considerations.asp

  Hepatitis C Treatment Considerations for Veterans and the Public […] The treatment section has been updated to include 8 weeks of glecaprevir pibrentasvir (Mavyret) in all HCV genotypes who are treatment-naive with compensated cirrhosis (CTP A) without a history of decompensation; 12 weeks can be considered for patients with poor prognostic factors. Treatment has been updated to include SOF-based therapy in patients with chronic kidney disease, including those on hemodialysis. […] Patients with acute HCV infection can be treated with DAAs upon initial diagnosis (based on detectable HCV RNA) without awaiting spontaneous resolution if appropriate. Selection for HCV treatment should include patients who become reinfected with HCV after initially achieving sustained virologic response. […] Treatment regimens for post transplant patients have been updated.

• #84 Clinical Care of Hepatitis C | Hepatitis C | CDC

  https://www.cdc.gov/hepatitis-c/hcp/clinical-care/index.html

  Hepatitis C can be cured in more than 95% of cases with just 8-12 weeks of well-tolerated oral-only treatment with direct-acting antiviral (DAA) agents. […] Curative DAA treatment is recommended for essentially everyone with hepatitis C. […] Available therapies can cure more than 95% of people infected with HCV within 812 weeks of therapy. […] Except for pregnant patients and children under 3, clinicians should treat people with detectable HCV RNA in their blood with oral DAA therapy. There is no need to wait for potential spontaneous viral resolution. […] DAA therapies are not approved for pregnant patients and children under 3. […] Your patient is considered cured of hepatitis C if there is no detectable HCV RNA after 12 weeks of treatment. This indicates they have had a sustained virologic response to therapy.

• #85 Hepatitis C | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/hepatitis-c

  In addition to the standard treatments, our team of certified pediatric hepatologists is also at the forefront of treatment research, treating adolescents with newly approved treatments for adults and conducting clinical trials to help make them available to children as young as 3 years of age. […] All children and adults with hepatitis C should be vaccinated against the other two major hepatitis viruses, hepatitis A and hepatitis B, in order to prevent additional liver inflammation and injury. There is currently no vaccine for hepatitis C. […] If left untreated or if treatment fails, chronic hepatitis C can last for decades. During that time, it can progressively damage the liver and lead to such complications as cirrhosis and liver cancer.

• #86 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits. […] Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 to the June 2021 approval of 2 pangenotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years. […] Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation. […] Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs.

• #87

  https://www.oregon.gov/oha/ph/diseasesconditions/hivstdviralhepatitis/adultviralhepatitis/pages/treatment.aspx

  There is a cure for hepatitis C (HCV) through highly effective medications with minimal side effects. […] Currently, direct acting antivirals (DAAs) are medications in pill form taken over 8-12 weeks with minimal side effects. Over 90% of people are cured of HCV after completing treatment. […] People must work with their providers to have ongoing monitoring for worsening liver damage or liver cancer. […] Thankfully, children as young as three years can be treated safely and effectively with DAAs.

• #88 Clinical Care of Hepatitis C | Hepatitis C | CDC

  https://www.cdc.gov/hepatitis-c/hcp/clinical-care/index.html

  Hepatitis C can be cured in more than 95% of cases with just 8-12 weeks of well-tolerated oral-only treatment with direct-acting antiviral (DAA) agents. […] Curative DAA treatment is recommended for essentially everyone with hepatitis C. […] Available therapies can cure more than 95% of people infected with HCV within 812 weeks of therapy. […] Except for pregnant patients and children under 3, clinicians should treat people with detectable HCV RNA in their blood with oral DAA therapy. There is no need to wait for potential spontaneous viral resolution. […] DAA therapies are not approved for pregnant patients and children under 3. […] Your patient is considered cured of hepatitis C if there is no detectable HCV RNA after 12 weeks of treatment. This indicates they have had a sustained virologic response to therapy.

• #89 Hepatitis C You Later! | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-c-you-later

  Glecaprevir/pibrentasvir, or Mavyret, is a second pan-genotypic regimen. […] Sofosbuvir/velpatasvir, or Epclusa, can be used for Genotypes 1, 2, and 4-6; patients with genotype 3 require baseline NS5A resistance-associated substitution testing. […] Both glecapravir/pibrentasvir and sofosbuvir/velpatasvir are highly effective in treatment-nave adults with compensated cirrhosis, regardless of HCV genotype. […] Treatment of HCV reduces all-cause mortality and also liver-related adverse consequences including cirrhosis and HCC. […] The goal of treatment is sustained virologic response, or SVR. […] Although cure rates are extremely high (95%), a small portion of patients will fail to respond to first line DAA therapy. […] Currently, hepatitis C treatment is contraindicated in patients who are pregnant or breastfeeding due to a lack of studies demonstrating their safety.

• #90

  https://www2.hse.ie/conditions/hepatitis-c/treatment/

  They’re effective at clearing the infection in more than 95% of people. […] You take the tablets for 8 to 12 weeks. The length of treatment depends on the type of hepatitis C you have. […] Direct-acting antivirals (DAAs) cure over 9 in 10 patients with hepatitis C. […] You need to complete the full course of treatment to clear the hepatitis C virus from your body. […] If your treatment is successful, you do not have any protection against another hepatitis C infection. […] Some hepatitis C medicines have not been tested in pregnancy. […] You should not become pregnant while taking treatment as it could be harmful to unborn babies. […] By not getting treatment you increase your chances of developing serious liver disease, cirrhosis, liver cancer, liver failure or end stage liver disease.

• #91 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits. […] Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 to the June 2021 approval of 2 pangenotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years. […] Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation. […] Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs.

• #92 What to Know About Hepatitis C Treatment | Saint Luke’s Health System

  https://www.saintlukeskc.org/health-library/what-know-about-hepatitis-c-treatment

  Most adults with hepatitis C virus (HCV) have the virus for the rest of their lives unless they are treated. If you have HCV in your body for at least 6 months, you have chronic hepatitis C. This means you need treatment to get rid of the virus. Medicines that cure over 95% of chronic hepatitis C cases were developed about 10 years ago. The medicines are taken by mouth for 8 to 12 weeks and don’t have a lot of side effects. Since this treatment (called direct-acting antiviral therapy) became available, treatment recommendations changed. Now everyone with chronic hepatitis C should be offered treatment. […] A cure is now possible for most people. […] For most people, treatment cures HCV and is a good choice. […] Newer treatment has few risks. […] It’s very important to take your medicines exactly as directed. You can’t miss any doses. […] It’s a good idea to treat HCV before you get pregnant.

• #93 Hepatitis C: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/177792-overview

  HCV infection has become a curable disease, although a vaccine does not yet exist. […] Treatment of acute hepatitis C has rapidly evolved and continues to evolve. […] Although direct-acting antiviral agents cure over 95% of individuals infected with HCV, no effective vaccine exists against hepatitis C. […] Treatment with a 12-week regimen of HCV antiviral agents can cost up to $95,000. […] The incremental cost-effectiveness ratio (ICER) for direct-acting antiviral agents (DAAs) remains up to $100,000 across all HCV genotypes and fibrosis stages. […] Patients with hepatitis C virus (HCV) infection should be advised to abstain from alcohol use, as it accelerates the onset of cirrhosis and end-stage liver disease. […] Patients should also check with a healthcare professional before taking any new prescription pills, over-the-counter drugs, or supplements, as these can potentially damage the liver.

• #94 Hepatitis C has a cure — but many Americans still lack access to it

  https://www.statnews.com/2023/06/29/hepatitis-c-cure-access/

  The CDC report notes that cure rates are lowest among people without health insurance or Medicaid coverage. […] Hepatitis C infections are worsening, said Adrienne Simmons, the director of programs at the National Viral Hepatitis Roundtable. […] Collins national hepatitis C elimination program aims to help people get tested faster by supporting the development and approval of rapid point-of-care viral tests for hepatitis C. […] Rapid tests would not only help people access treatment faster, but also help curb the spread of new hepatitis C infections. […] The White House backed program also aims to establish a national hepatitis C drug delivery model that would lower the cost of the treatment by negotiating and purchasing a large quantity of the medications at a fixed price. […] If we could right now find, over the course of five years, those people who are hep C positive and get them cured, we’d save the government about $13.3 billion in the first 10 years. […] Without treating individuals who are incarcerated, especially those in prisons, we’re not going to achieve elimination of hepatitis C in the U.S., she said. […] Collins said the new CDC report underscores the need for a bold, strategic response to eliminate hepatitis C.

• #95 Clinical Practice Guidance for Testing, Managing, and Treating Hepatitis C Virus Infection: 2023 Update by AASLD-IDSA

  https://www.idsociety.org/practice-guideline/hcv-guidance/

  The Guidance Panel suggests that DAA treatment may be considered during pregnancy on a case-by-case basis after a discussion of potential risks and benefits. […] Treatment for HCV infection in children has been revolutionized in recent years, beginning with the US Food and Drug Administration approval of the first DAAs for adolescents in April 2017 to the June 2021 approval of 2 pangenotypic regimens (glecaprevir/pibrentasvir and sofosbuvir/velpatasvir) for children as young as 3 years. […] Clinical trial and real-world data provide robust evidence supporting the safety and efficacy of HCV DAA treatment in patients who have undergone solid organ transplantation. […] Given that available data support the safety and efficacy of DAA therapy in the posttransplant setting, many transplant centers have begun using solid organs from HCV-positive donors for HCV-negative recipients to increase the pool of available organs.

• #96 How to Beat Hep C Naturally

  https://www.healthline.com/health/hepatitis-c/how-to-beat-hep-c-naturally

  Theres no clear evidence that natural treatments, such as herbs, vitamins, or certain foods, can help cure hepatitis C. However, some may support liver health overall and reduce symptoms. […] Hepatitis C usually requires treatment with antiviral medications to clear the virus from the body. […] Theres no natural remedy to cure hepatitis C. […] However, some herbs, vitamins, supplements, and foods may improve symptoms or help protect the liver from damage. […] Before starting any alternative treatment, discuss the benefits and risks with a doctor. […] Some alternative treatments can cause unwanted side effects or even interfere with hepatitis C medications and make them less effective. […] But currently, no herbal remedy shows clear benefits for clearing the hepatitis C virus. […] In general, theres currently not enough high quality evidence to support the use of milk thistle in treating hepatitis C.

• #97 Treatment for Hepatitis C (HCV) – American Liver Foundation

  https://liverfoundation.org/liver-diseases/viral-hepatitis/hepatitis-c/treating-hepatitis-c/

  No dietary supplement has been shown to be effective for Hepatitis C or its complications. […] The results of research supported by the NIH have shown that silymarin, the active extract of milk thistle and the most popular complementary health product taken by people with liver disease was no more effective than placebo in people with Hepatitis C. […] Its important to tell your doctor about everything you’re taking before starting treatment for Hepatitis C.

• #98 How to Beat Hep C Naturally

  https://www.healthline.com/health/hepatitis-c/how-to-beat-hep-c-naturally

  Research suggests that people with HCV infection may be deficient in zinc. […] Zinc supplementation helped prevent liver deterioration and reduced the rate of liver cancer compared with people who didnt take a zinc supplement. […] Research suggests probiotic supplements can improve liver inflammation and stop the progression of liver fibrosis. […] Theres no special dietary plan to help treat or cure hepatitis C. […] Several studies have shown that drinking three or more cups of coffee can improve liver health in people with hepatitis C. […] A 2021 study linked a diet rich in fish to a lower viral load in people with chronic hepatitis C. […] The Food and Drug Administration (FDA) does not test natural herbs and dietary supplements to the same standards as prescription and over-the-counter medications.

• #99 How to Beat Hep C Naturally

  https://www.healthline.com/health/hepatitis-c/how-to-beat-hep-c-naturally

  Antiviral medications for hepatitis C have improved significantly in recent years. […] These newer drugs cure the hepatitis C infection in over 90% of people. […] Newer antiviral treatments can cure hepatitis C in as little as 8 weeks. […] However, once you have a chronic hepatitis C infection, the only way to cure it is with prescribed antiviral medications.

• #100 Current and future strategies for the treatment of chronic hepatitis C

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8046635/

  Treatment as prevention is evolving as a major strategy for the treatment of HCV. Iceland initiated the Treatment As Prevention For Hepatitis C Program in 2016 with the aim of treating every patient with HCV free of charge. Within 3 years of initiation, 98% of those confirmed with HCV RNA positive testing initiated DAA therapy with an overall SVR rate of 89%. […] Hepatitis C infection is straightforward to treat and difficult to eliminate. We already have the tools to successfully treat the vast majority of individuals who are diagnosed with HCV. However, elimination of HCV will require a strong commitment from governments and payors to provide funding for education, diagnosis, and treatment.

• #101

  https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

  With proper treatment, many people can be cured from hepatitis C infection and live healthy lives. […] Access to HCV treatment is improving but remains limited. Of the 50 million people living with HCV infection globally in 2022, an estimated 36% people knew their diagnosis, and of those diagnosed with chronic HCV infection, around 20% (12.5 million) people had been treated with DAAs by the end of 2022.

• #102 Treatment of Hepatitis C | Hepatitis C | CDC

  https://www.cdc.gov/hepatitis-c/treatment/index.html

  Hepatitis C can be cured. […] Treatment that cures hepatitis C is available. […] Early treatment can prevent serious complications like liver scarring, liver cancer and death. […] If you are diagnosed with hepatitis C, talk to your doctor right away about getting treatment that is right for you. […] Don’t wait! There are oral medications (pills) available called direct-acting antivirals (DAAs) that: Cure more than 95% of people in just 8-12 weeks. […] If you are being treated for hepatitis C, talk to your doctor if you have any of the following symptoms: Extreme dizziness or fatigue. […] If you are diagnosed with hepatitis C and receiving treatment you should: Eat a well-balanced diet. […] Get tested for HIV and hepatitis B. […] Get vaccinated against hepatitis A and hepatitis B. […] Have your liver checked regularly (every 3-6 months) if you have been diagnosed with cirrhosis.

• #103 Hepatitis C: Symptoms, What It Is, How You Get It, Treatment

  https://my.clevelandclinic.org/health/diseases/15664-hepatitis-c

  Hepatitis C is a liver infection that the hepatitis C virus (HCV) causes. There are medications that cure hepatitis C and reduce the risk of serious complications. […] Treatment can cure hepatitis C. […] The most common treatment for chronic hepatitis C is direct-acting antiviral (DAA) medication. DAAs reduce the amount of virus in your body. […] Research shows these medications cure most cases of chronic hepatitis C. […] Yes, it can. About 25% of people with acute hepatitis C recover completely, meaning the virus goes away. And treatment can cure chronic hepatitis C if you receive a diagnosis and treatment before the infection causes serious liver damage. […] Medication can cure hepatitis C.

• #104 When and in Whom to Initiate HCV Therapy | HCV Guidance

  https://www.hcvguidelines.org/evaluate/when-whom

  Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. […] Therefore, the panel continues to recommend treatment for all patients with chronic HCV infection, except those with a short life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy. […] A well-established therapeutic relationship between clinician and patient remains crucial for optimal outcomes with direct-acting antiviral (DAA) therapies. […] The goal of treatment of HCV-infected persons is to reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response.

• #105 Hepatitis C You Later! | AASLD

  https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatitis-c-you-later

  Direct-acting antivirals have revolutionized treatment of HCV. […] They have allowed us to expand the donor pool to include HCV-positive donors for HCV-negative recipients, and treat recipients post-transplantation with extremely high rates of cure. […] Simplified treatment in HCV without cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks). […] Simplified treatment for HCV with compensated cirrhosis is with either glecaprevir/pibrentasvir (8 weeks) or sofosbuvir/velpatasvir (12 weeks, genotype 3 requires NS5A resistance testing). […] Ledipasvir/sofosbuvir (genotypes 1,4,5,6) and sofosbuvir/velpatasvir (pan-genotypic, NS5A resistance testing in genotype 3) are preferred regimens in decompensated cirrhosis. […] DAAs have revolutionized the management of HCV, and have cure rates well above 95%.

• #106

  https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

  With proper treatment, many people can be cured from hepatitis C infection and live healthy lives. […] Access to HCV treatment is improving but remains limited. Of the 50 million people living with HCV infection globally in 2022, an estimated 36% people knew their diagnosis, and of those diagnosed with chronic HCV infection, around 20% (12.5 million) people had been treated with DAAs by the end of 2022.

• #107 Breakthroughs in hepatitis C research: from discovery to cure | Nature Reviews Gastroenterology & Hepatology

  https://www.nature.com/articles/s41575-022-00608-8

  In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. […] Today, HCV infection remains a global health burden and a major cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation. […] However, tremendous advances have been made over the decades, and HCV became the first curable, chronic viral infection. […] The introduction of direct antiviral agents revolutionized antiviral treatment, leading to viral eradication in more than 98% of all patients infected with HCV. […] This Perspective discusses the history of HCV research, which reads like a role model for successful translational research: starting from a clinical observation, specific therapeutic agents were developed, which finally were implemented in national and global elimination programmes.

Zobacz więcej